Force requirements and insulin delivery profiles of four injection devices

Kenichi Toraishi, Yoichi Yuizono, Noriko Nakamura, Shino Kato, Tsuyoshi Aoki, Kenji Ashida, Yasuhiro Sako

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Injection force requirements for four insulin pen-type injection devices were evaluated using the AGS-IkNG Autograph force measurement device (Shimadzu Corp., Kyoto, Japan). Results: Compared with the Humulin® Pen (the Japanese brand name is Humacart® kit; the same device as the Humalog® Pen; Eli Lilly, Indianapolis, IN), HumaPen® Ergo (Eli Lilly), and NovoPen® 3 (Novo Nordisk A/S, Bagsvaerd, Denmark), the InnoLet® (Novo Nordisk) required the lowest injection force to both initiate piston movement and commence insulin delivery and required the lowest overall force throughout delivery. InnoLet and NovoPen 3 showed the most even load-displacement curves, suggesting a smoother delivery of insulin during injection. In contrast, the Humulin Pen and HumaPen Ergo demonstrated marked fluctuations in the force required to complete injection. Conclusions: These performance characteristics appeared consistent with mechanical features of these insulin delivery devices, and the results highlight the potential importance of careful pen selection for patients with neuromuscular weakness or impaired manual coordination.

Original languageEnglish
Pages (from-to)629-635
Number of pages7
JournalDiabetes Technology and Therapeutics
Volume7
Issue number4
DOIs
Publication statusPublished - Aug 1 2005

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Force requirements and insulin delivery profiles of four injection devices'. Together they form a unique fingerprint.

  • Cite this

    Toraishi, K., Yuizono, Y., Nakamura, N., Kato, S., Aoki, T., Ashida, K., & Sako, Y. (2005). Force requirements and insulin delivery profiles of four injection devices. Diabetes Technology and Therapeutics, 7(4), 629-635. https://doi.org/10.1089/dia.2005.7.629